Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.

about

KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis.Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.

P2860

Q52648806-9D8F488A-9879-4E0F-A913-FAC2AB95EFDB Q55498607-36E28CC3-4E89-4A9A-A527-48ACC56F8BB9

P2860

Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.

Item

http://www.wikidata.org/entity/Q38685245

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Anti-steatotic and anti-fibrot ...... n non-alcoholic liver disease.

@en

type

Item

label

Anti-steatotic and anti-fibrot ...... n non-alcoholic liver disease.

@en

prefLabel

Anti-steatotic and anti-fibrot ...... n non-alcoholic liver disease.

@en

P1476

Anti-steatotic and anti-fibrot ...... n non-alcoholic liver disease.

@en

P2093

Bin Duan

http://www.w3.org/2001/XMLSchema#string

David E Smith

http://www.w3.org/2001/XMLSchema#string

Dawoon Jung

http://www.w3.org/2001/XMLSchema#string

Itzhak D Goldberg

http://www.w3.org/2001/XMLSchema#string

Jiaqi Shi

http://www.w3.org/2001/XMLSchema#string

Jing-Song Li

http://www.w3.org/2001/XMLSchema#string

Kai Jiang

http://www.w3.org/2001/XMLSchema#string

Latha Paka

http://www.w3.org/2001/XMLSchema#string

Michael Yamin

http://www.w3.org/2001/XMLSchema#string

Ping Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Modulators of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels and their Therapeutic Indications

The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease

Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis

Lipotoxicity in HepG2 cells triggered by free fatty acids

Effects of long-term ethanol administration in a rat total enteral nutrition model of alcoholic liver disease

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.

P304

4181-4190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V23.I23.4181

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28694658

http://www.w3.org/2001/XMLSchema#string

P932

5483492

http://www.w3.org/2001/XMLSchema#string

Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.

about

P2860

P2860

Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932